At Hospital Universitario Fundación Jiménez Díaz, specialists showed patients and trainees how blood counts, cellular studies, and genetic tests shape hematology care. The meeting also covered new treatments, transfusion support, research, and patient services.
At Hospital Universitario Fundación Jiménez Díaz, specialists told patients and trainees that a blood count can point to a problem but cannot define every hematological disease. The Madrid hospital organised the first Jornada por la Semana de la Hematología with BeOne Medicines for patients, families, students, and healthcare professionals in training. Speakers explained how diagnosis guides treatment. They also discussed follow-up and research.
Hematological disorders are not interchangeable. Álvaro Arriero García said the hemogram provides the first direction. Doctors then examine blood cells and their characteristics to identify the disease more accurately. Genetic and molecular studies add further detail. That information can change how clinicians classify a condition and choose therapy.
In complex cases, the picture may also require immunological and cytogenetic analysis. One laboratory result is not enough.
Integrated diagnostic committees bring the findings together. Specialist groups also focus on diseases such as lymphoma or myeloma. Juan Carlos Caballero described how these teams use the available evidence to guide clinical decisions. An abnormal result becomes a structured assessment. It does not become a final diagnosis on its own.
That is the core issue.
Pilar Llamas Sillero, who heads the hospital's Hematology Service, presented the meeting as a way to show the breadth of the specialty. She also outlined the care pathway from the first signs of illness through diagnosis, treatment, and monitoring. Sergio Ramos Cillán said the programme covered blood and bone marrow function, coagulation disorders, new treatments, and research. The organisers also discussed the balance between bleeding and thrombosis, another central part of hematology.
Доступный поиск не выявил проверяемых новых цифр, последующих обновлений или независимых комментариев, непосредственно связанных с этим мероприятием. Найденные материалы ВОЗ дают общий контекст по бремени заболеваний, но не содержат релевантной статистики именно по гематологическим болезням или Испании.
Genetics raised a separate issue for families. Ana del Río Machín, a biologist with the Hematology Research Group at Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), distinguished acquired alterations in tumour cells from germline variants. Some germline variants may be inherited and can increase susceptibility to certain hematological neoplasms. The difference affects how specialists understand a disease. It also shows when family predisposition needs attention.
The programme covered more than diagnosis. Isabel Iturrate Barasan explained the route blood takes before transfusion and the role of donors. She presented Hemotherapy as an essential part of hematology. Javier Cornago Navascues discussed the growing range of treatments. He said doctors can adapt them more closely to the disease and the patient's circumstances.
CAR-T therapies were among the advanced options discussed. Laura Solán Blanco explained that these treatments modify T lymphocytes so they can recognise and attack tumour cells. Doctors use them in certain leukemias, lymphomas, and cases of multiple myeloma. The treatment requires specialised teams and coordinated patient care.
Support also extends beyond the hospital room. The Asociación Española Contra el Cáncer (AECC) presented resources for patients and relatives dealing with emotional, social, and physical needs during treatment. Its exercise programme for oncohematology patients involves Hospital Universitario Fundación Jiménez Díaz. The programme also includes joint research into its impact. That patient focus connects with Madrid's healthcare debate, but the meeting stayed focused on the demands of hematology.
Clinical research completed the agenda. Lucía Pavía Pascual explained that patients can be offered clinical trials at early stages of illness, including first-line treatment. The trials assess new therapies through close follow-up and informed patient participation. New treatment can reach routine care through that defined clinical process.
The clearest value of the Jornada por la Semana de la Hematología was its direct explanation of clinical decisions. The hemogram starts the investigation. Cellular, genetic, and molecular evidence refines it. Multidisciplinary teams connect the findings to treatment. Follow-up can include transfusion support, research, and patient assistance.
Accurate diagnosis is the foundation of safer, more personalised hematology care.
